Board Meetings for SUNPHARMA
Detailed list of historic and upcoming board meetings.
| Symbol | Company | Meeting Date | Purpose | Description | Links |
|---|---|---|---|---|---|
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 14 Aug 2018 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2018 | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 25 May 2018 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2018 and dividend | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 14 Feb 2018 | Results | To consider and take on record, the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2017. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 14 Nov 2017 | Results | to consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2017. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 11 Aug 2017 | Results | To consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2017. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 26 May 2017 | Results/Dividend | Interalia, to transact the following business : (i) To consider and approve standalone and consolidated Audited Financial Results of the Company for the quarter and year ended March 31, 2017. (ii) To consider recommendation of dividend for the year ended March 31, 2017 subject to the approval of the shareholders at the ensuing Annual General Meeting. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 14 Feb 2017 | Results | To consider and take on record the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2016. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 10 Nov 2016 | Results/Others | To transact, interalia, the following business: a. To consider and take on record the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016.b. To consider the proposal for the merger/amalgamation of Ranbaxy Drugs Limited, Vidyut Investments Limited, Gufic Pharma Limited and Sun Pharma Medisales Private Limited (formerly known as Solrex Pharmaceutical Company), all four companies being wholly owned subsidiaries of Sun Pharmaceutical Industries Ltd., with Sun Pharmaceutical Industries Ltd subject to receipt of necessary approvals. In view of the consideration of above items, the window closure for trading by designated persons as per Insider Trading Rules of the Company will be from November 1, 2016 to November 14, 2016 (both days inclusive). | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 12 Aug 2016 | Results | interalia, to consider and take on record the Unaudited Financial Results of the Company for the quarter ended June 30, 2016. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 23 Jun 2016 | Buyback | For evaluating a proposal of Buy Back of Equity Shares of the Company. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 30 May 2016 | Results/Dividend | interalia, to transact the following business :(i) To consider and approve standalone and consolidated Audited Financial Results of the Company for the year ended March 31, 2016.(ii) To consider recommendation of dividend for the year ended March 31, 2016 subject to the approval of the shareholders at the ensuing Annual General Meeting. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 12 Feb 2016 | Results/Others | interalia, to consider and take on record the Unaudited Financial Results of the Company for the Third quarter and nine months ended December 31, 2015. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 07 Nov 2015 | Results | Interalia, to consider and take on record the Unaudited Financial Results of the Company for the second quarter and six months ended September 30, 2015. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 11 Aug 2015 | Results/Dividend | Sun Pharmaceuticals Industries Limited had informed the Exchange that the meeting of the Board of Directors of the Company will be held on August 11, 2015, Interalia, to consider and take on record the Unaudited Financial Results of the Company for the first quarter and three months ended June 30, 2015.The Company has now informed the Exchange that the Hon'ble High Court of Gujarat, at Ahmedabad at its hearing held on July 30, 2015 has approved the Scheme of Amalgamation of Sun Pharma Global Inc. (SPGI), wholly-owned subsidiary of the Company, into Sun Pharmaceutical Industries Limited (SPIL) with effect from the appointed date of January 1, 2015. This is to further inform you that the certified copy of the High Court order is expected to be received shortly and will be filed with the Registrar of Companies there after as required and the process of merger would get completed on such filing.The Board of Directors of the Company at its meeting scheduled to be held on August 11, 2015 would also transact the following business:(i) Consideration of the revised audited annual accounts of the Company for the year ended 31st March, 2015 after giving the effect to the above mentioned Scheme of Amalgamation of SPGI into SPIL and the proposal for payment of dividend.(ii) Consideration of the recommendation of payment of dividend on equity shares for the year ended March 31, 2015 subject to the approval of the shareholders at the ensuing Annual General Meeting. | |
| SUNPHARMA | Sun Pharmaceutical Industries Limited | 11 Aug 2015 | Results | Interalia, to consider and take on record the Unaudited Financial Results of the Company for the first quarter and three months ended June 30, 2015. |